500. A Real-World Cohort Study of Bamlanivimab Versus Bamlanivimab-Etesevimab for Non-severe COVID-19

BACKGROUND: Anti-spike monoclonal antibodies (mAb) including Bamlanivimab (BAM) and Bamlanivimab-Etesevimab (BAM/E) have shown reduced hospitalization rates for non-severe coronavirus disease 2019 (COVID-19) in clinical trials. Recent studies provided real-world hospitalization rates for BAM. But, s...

Descripción completa

Detalles Bibliográficos
Autores principales: Monday, Lea, Alangaden, George J, Brar, Indira, Mayur, Ramesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8690676/
http://dx.doi.org/10.1093/ofid/ofab466.699

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8690676/
http://dx.doi.org/10.1093/ofid/ofab466.699

Ejemplares similares